← All trials
NCT06077760
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 6, 2023
- Primary completion
- Jun 25, 2030
- Completion date
- Dec 21, 2035
- First posted
- Oct 11, 2023
- Last posted
- Dec 19, 2023
- Enrollment
- 868
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MerckLead sponsor
- MerckStudy director
- Moderna TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.